Don't miss real-time top news, insights, and interviews with the experts direct from the conference floor in Chicago. Sign up now to be reminded to tune in to OncLive News Network: On Location in Chicago.

General Discussions

Melanoma Advances: Where We Are and Where We're Going

By Douglas B. Johnson, MD

The biggest advance that the melanoma space has seen in recent years is the advent of combination therapies, according to Douglas B. Johnson, MD, clinical director of the Melanoma Research Program and assistant professor of Medicine at Vanderbilt University Medical Center. 

Response rates have increased thanks to the combination of immunotherapy agents, as well as combining BRAF and MEK inhibitors. 

Now, researchers are looking ahead, with clinical trials assessing PD-1 inhibitors with novel immune mechanisms or targeted agents, as well as the pairings of oncolytic viruses with checkpoint inhibitors. Johnson said that hopefully these trials will lead to improved clinical benefit for patients with the disease.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.